Insulin and Insulin Analogs

 

Insulin

The Competitive Intelligence Report Insulin and Insulin Analogs as of March 2007 provides a competitor analysis in the development pipeline of next generation products for the treatment of diabetes.

The report describes the market size and sales figures of the insulin and insulin analog products for 2006 and the challenges imposed by biogenerics (syn.: biosimilar , follow-on biologic , follow-on protein ) and improved first generation therapeutic proteins by use of drug delivery technologies to prolong half-life. The report compiles in detail next generation insulin projects using non-invasive drug delivery technologies for inhaled, nasal, transdermal and oral administration and also engineered insulin molecules.

Among the companies with first and second generation insulin products affected by biogenerics and innovative non-invasive delivery are Eli Lilly, Sanofi-Aventis, Novo Nordisk and Pfizer. Among the companies with competitor projects are Wockhardt, Flamel Technologies, Emisphere Technologies, CoGenesys and and many more.